NCT03333343 2026-01-16
Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC
Novartis
Phase 1 Active not recruiting
Clinical Trials
11 trialsNCT03599518 2023-02-08
DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
Daiichi Sankyo
Phase 1 Terminated
NCT02088112 2022-04-04
MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).
MedImmune LLC
Phase 1 Completed
NCT04390984 2021-01-11
Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Unknown
NCT02374645 2020-04-24
A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC
Hutchmed
Phase 1 Completed
NCT00162318 2015-10-28
A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Eli Lilly and Company
Phase 1 Completed
NCT01602289 2015-06-08
A Study of LY2875358 in Japanese Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT00255489 2011-01-25
A Phase I Study of ZD1839 and Palliative Thoracic Radiotherapy in Patients With Non-small-cell Lung Cancer
AstraZeneca
Phase 1 Completed
NCT00502060 2009-05-14
Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer
AstraZeneca
Phase 1 Completed
NCT00127829 2009-04-23
AGUS
AstraZeneca
Phase 1 Completed
NCT00252798 2007-12-19
ZD1839 (Iressaâ„¢) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer
AstraZeneca
Phase 1 Completed